Arvinas, Inc. (ARVN)
| Market Cap | 585.85M +11.0% |
| Revenue (ttm) | 89.40M -79.1% |
| Net Income | -221.30M |
| EPS | -3.22 |
| Shares Out | 64.52M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 968,096 |
| Open | 9.30 |
| Previous Close | 9.42 |
| Day's Range | 8.87 - 9.36 |
| 52-Week Range | 5.90 - 14.51 |
| Beta | 1.80 |
| Analysts | Buy |
| Price Target | 15.83 (+74.34%) |
| Earnings Date | May 12, 2026 |
About ARVN
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins. It is also developing clinical development programs , including ARV-102, a leucine-rich repeat kinase 2 (LRRK2) protein for the treatment of neurodegenerative diseases, suc... [Read more]
Financial Performance
In 2025, Arvinas's revenue was $262.60 million, a decrease of -0.30% compared to the previous year's $263.40 million. Losses were -$80.80 million, -59.38% less than in 2024.
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for ARVN stock is "Buy." The 12-month stock price target is $15.83, which is an increase of 74.34% from the latest price.
News
Arvinas price target raised to $16 from $14 at BofA
BofA analyst Tazeen Ahmad raised the firm’s price target on Arvinas (ARVN) to $16 from $14 and keeps a Neutral rating on the shares. Arvinas and Pfizer (PFE) entered into…
Arvinas price target raised to $18 from $16 at BTIG
BTIG raised the firm’s price target on Arvinas (ARVN) to $18 from $16 and keeps a Buy rating on the shares. Along with its Q1 results, the company announced it…
Arvinas price target raised to $20 from $18 at Barclays
Barclays raised the firm’s price target on Arvinas (ARVN) to $20 from $18 and keeps an Overweight rating on the shares post the Q1 report. The firm says the company’s…
H.C. Wainwright says Pfizer handing off Veppanu to Rigel ‘makes strategic sense’
After Rigel Pharmaceuticals (RIGL) announced it has entered into an exclusive global licensing agreement with Pfizer (PFE) and Arvinas (ARVN) for Veppanu for the treatment of ER+/HER2-, ESR1-mutated a...
Arvinas, Pfizer enter license pact with Rigel Pharmaceuticals for Veppanu
Arvinas (ARVN) and Pfizer (PFE) have entered into a license agreement with Rigel Pharmaceuticals (RIGL) for the exclusive global development, manufacturing, and commercialization rights for Veppanu. V...
Rigel Pharmaceuticals enters license agreement with Arvinas, Pfizer
Rigel Pharmaceuticals (RIGL) announced that it has entered into an exclusive, global license agreement with Arvinas (ARVN) and Pfizer (PFE), subject to regulatory clearance, to develop, manufacture an...
Rigel strikes licensing deal for Pfizer and Arvinas' breast cancer drug
Rigel Pharmaceuticals said on Tuesday it has struck a global licensing deal for Arvinas and Pfizer's recently approved breast cancer drug, marking Rigel's fourth commercial product on the market.
Arvinas Earnings Call Transcript: Q1 2026
FDA approval of VEPPANU and a global licensing deal with Rigel mark a pivotal quarter, enabling focus on a robust pipeline in oncology and neurology. Revenue and expenses declined year-over-year, with a strong cash position supporting operations into 2028.
Arvinas reports Q1 EPS (90c), consensus (63c)
Reports Q1 revenue $15.6M, consensus $34.84M. “The approval of VEPPANU is a defining achievement for Arvinas (ARVN) and reflects the culmination of more than a decade of focused work to…
Arvinas Reports First Quarter 2026 Financial Results and Provides Corporate Update
– First-ever FDA approved PROTAC supports the further development and potential of Arvinas' pipeline – – Announced FDA Approval of VEPPANU ™ (vepdegestrant) for the treatment of ESR1m, ER+/HER2- advan...
Arvinas and Pfizer Enter into a Transaction with Rigel Pharmaceuticals for the Exclusive Global Rights of VEPPANU (vepdegestrant)
– Arvinas and Pfizer to receive $85 million in upfront and transition payments with potential for additional $320 million in development, regulatory, and commercial milestones and tiered royalites on ...
Arvinas to Report First Quarter 2026 Financial Results on May 12, 2026
NEW HAVEN, Conn., May 05, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company working to create a new class of drugs based on targeted protein degradation, today announced t...
Arvinas management to meet with BTIG
Biotechnology Analyst Mukherjee holds a group dinner meeting with management in New York on May 7 at 6 pm hosted by BTIG.
Arvinas price target raised to $24 from $21 at Citi
Citi raised the firm’s price target on Arvinas (ARVN) to $24 from $21 and keeps a Buy rating on the shares after the company received FDA approval of Veppanu for…
Arvinas gets early approval for Vepdeg, says Truist
Arvinas (ARVN) received early approval of Vepdeg ahead of its June 5, 2026 PDUFA date, marking both the company’s first approval and the first PROTAC degrader approved in breast cancer,…
Arvinas announces FDA approval of VEPPANU for ESR1m, ER+/HER2- ABC
Arvinas (ARVN) with its partner Pfizer (PFE), announced that the U.S. Food and Drug Administration has granted approval for VEPPANU for the treatment of adults with estrogen receptor-positive/human ep...
Arvinas Announces FDA Approval of VEPPANU (vepdegestrant) for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer
– VEPPANU™ is the first-and-only FDA-approved PROTAC, a type of heterobifunctional protein degrader – – Approval received in advance of FDA-assigned PDUFA date of June 5, 2026; Arvinas and Pfizer rema...
US FDA approves Pfizer, Arvinas' breast cancer drug
The U.S. Food and Drug Administration on Friday approved Pfizer and Arvinas' drug for a type of breast cancer.
Arvinas trading halted, news pending
11:22 EDT Arvinas (ARVN) trading halted, news pending
Arvinas price target raised to $21 from $18 at Citi
Citi raised the firm’s price target on Arvinas (ARVN) to $21 from $18 and keeps a Buy rating on the shares. The firm increased its probability of success for ARV-102…
Arvinas presents data from Phase 1 clinical trial of ARV-102
Arvinas (ARVN) presented data from a Phase 1 clinical trial of ARV-102, an investigational PROteolysis TArgeting Chimera, or PROTAC, degrader designed to specifically target and degrade leucine-rich r...
Arvinas Announces Positive Phase 1 Data for ARV-102 Showing Greater Than 50% LRRK2 Degradation in the CSF of Patients with Parkinson's Disease Treated for 28 Days
– ARV-102 reduced endolysosomal and neuroinflammatory biomarkers implicated in Parkinson's disease and progressive supranuclear palsy –
Arvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2 Degrader, in Oral Session at the 2026 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders
– Company to highlight new safety, pharmacokinetic, and pharmacodynamic data from Phase 1 clinical trial of ARV-102 in participants with Parkinson's disease –
Arvinas Transcript: Barclays 28th Annual Global Healthcare Conference
Four clinical programs are in phase I, with vepdegestrant awaiting FDA approval and partnership. LRRK2 and KRAS degraders show strong differentiation and rapid progress, with key data readouts and new trials expected this year. Multiple milestones are targeted through 2026.